Predicting the Need for Biopsy to Detect Clinically Significant Prostate Cancer in Patients with a Magnetic Resonance Imaging–detected Prostate Imaging Reporting and Data System/Likert ≥3 Lesion: Development and Multinational External Validation of the Imperial Rapid Access to Prostate Imaging and Diagnosis Risk Score

Falagario U.G.; Reddy D.; Picker W.; Cucchiara V.; Stabile A.; Eldred-Evans D.; Bass E.; Gordon S.; Ahmed H.U.; Taimen P.; van Rossum P.S.N.; Verhoeff J.J.C.; Martini A.; Montoya Perez I.; Boström P.J.; Nordström T.; Wong K.; Aronen H.J.; Knaapila J.; Lantz A.; Connor M.J.; Peters M.; Qazi H.; Kurver P.; Gandaglia G.; Briganti A.; Shah T.T.; Winkler M.; Tam H.; Jambor I.; Ettala O.; Haug E.S.; Fossati N.; Tanaka M.B.
Predicting the Need for Biopsy to Detect Clinically Significant Prostate Cancer in Patients with a Magnetic Resonance Imaging–detected Prostate Imaging Reporting and Data System/Likert ≥3 Lesion: Development and Multinational External Validation of the Imperial Rapid Access to Prostate Imaging and Diagnosis Risk Score

Falagario U.G.
Reddy D.
Picker W.
Cucchiara V.
Stabile A.
Eldred-Evans D.
Bass E.
Gordon S.
Ahmed H.U.
Taimen P.
van Rossum P.S.N.
Verhoeff J.J.C.
Martini A.
Montoya Perez I.
Boström P.J.
Nordström T.
Wong K.
Aronen H.J.
Knaapila J.
Lantz A.
Connor M.J.
Peters M.
Qazi H.
Kurver P.
Gandaglia G.
Briganti A.
Shah T.T.
Winkler M.
Tam H.
Jambor I.
Ettala O.
Haug E.S.
Fossati N.
Tanaka M.B.
Katso/Avaa
Lataukset: 

Elsevier B.V.
doi:10.1016/j.eururo.2022.07.022
URI
https://doi.org/10.1016/j.eururo.2022.07.022
Näytä kaikki kuvailutiedot
Julkaisun pysyvä osoite on:
https://urn.fi/URN:NBN:fi-fe2022102463098
Tiivistelmä

Background: Although multiparametric magnetic resonance imaging (MRI) has high
sensitivity, its lower specificity leads to a high prevalence of false-positive lesions requir-
ing biopsy.
Objective: To develop and externally validate a scoring system for MRI-detected Prostate
Imaging Reporting and Data System (PIRADS)/Likert 3 lesions containing clinically sig-
nificant prostate cancer (csPCa).
Design, setting, and participants: The multicentre Rapid Access to Prostate Imaging and
Diagnosis (RAPID) pathway included 1189 patients referred to urology due to elevated
age-specific prostate-specific antigen (PSA) and/or abnormal digital rectal examination (DRE); April 27, 2017 to October 25, 2019.

Kokoelmat